Lineage Cell Therapeutics Q2 2024 Update

TL;DR

Lineage Cell Therapeutics has $103.5M cash, $174.7M assets, $24.3M liabilities, and a $16.1M net loss for Q2.

AI Summary

Lineage Cell Therapeutics, Inc. reported its financial results for the period ending June 30, 2024. The company's cash and cash equivalents stood at $103.5 million as of June 30, 2024. Total assets were $174.7 million, while total liabilities were $24.3 million. The company's net loss for the three months ended June 30, 2024, was $16.1 million.

Why It Matters

This filing provides investors with a snapshot of Lineage Cell Therapeutics' financial health and operational performance, including their cash position and net loss, which are crucial for assessing their ability to fund ongoing research and development.

Risk Assessment

Risk Level: medium — The company reported a net loss, indicating ongoing operational costs exceeding revenue, which is typical for biotech but requires careful financial management.

Key Numbers

• $103.5M — Cash and Cash Equivalents (As of June 30, 2024, indicating liquidity.)
• $174.7M — Total Assets (As of June 30, 2024, representing the company's total resources.)
• $24.3M — Total Liabilities (As of June 30, 2024, showing the company's financial obligations.)
• $16.1M — Net Loss (For the three months ended June 30, 2024, reflecting operational expenses.)

Key Players & Entities

• Lineage Cell Therapeutics, Inc. (company) — Filer
• 2024-06-30 (date) — Period end date
• $103.5 million (dollar_amount) — Cash and cash equivalents as of June 30, 2024
• $174.7 million (dollar_amount) — Total assets as of June 30, 2024
• $24.3 million (dollar_amount) — Total liabilities as of June 30, 2024
• $16.1 million (dollar_amount) — Net loss for the three months ended June 30, 2024

FAQ

Filing Documents

• lctx-20240630.htm (10-Q) — 2017KB
• lctx-ex10_1.htm (EX-10.1) — 409KB
• lctx-ex31_1.htm (EX-31.1) — 14KB
• lctx-ex31_2.htm (EX-31.2) — 12KB
• lctx-ex32_1.htm (EX-32.1) — 9KB
• 0000950170-24-094004.txt ( ) — 9192KB
• lctx-20240630.xsd (EX-101.SCH) — 1271KB
• lctx-20240630_htm.xml (XML) — 1513KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Comprehensive Loss 7 Condensed Consolidated Statements of Changes in Shareholders' Equity 8 Condensed Consolidated Statements of Cash Flows 10 Notes to the Condensed Consolidated Interim Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Result of Operations

Management's Discussion and Analysis of Financial Condition and Result of Operations 28 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 36 PART II. OTHER INFORMATION 37 Item 1.

Legal Proceedings

Legal Proceedings 37 Item 1A.

Risk Factors

Risk Factors 37 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 37 Item 3. Defaults Upon Senior Securities 37 Item 4. Mine Safety Disclosures 37 Item 5. Other Information 37 Item 6. Exhibits 38

Signatures

Signatures 39 2 SPECI AL NOTE REGARDING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations" of this report, but are also contained elsewhere in this report. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this report are forward-looking statements. In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements in this report include, but are not limited to, statements about: the potential to receive developmental, regulatory, and commercialization milestone and royalty payments under our Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc.; our plans to research, develop and commercialize our product candidates; the initiation, progress, success, cost and timing of our clinical trials and other product development activities; the therapeutic potential of our product candidates, and the indications for which we intend to develop our product candidates; our ability to successfully manufacture our product candidates for clinical development and, if approved, for commercialization, and the timing and c

View Full Filing

View this 10-Q filing on SEC EDGAR